Registered title, quoted from ClinicalTrials.gov
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Peking University Cancer Hospital; 1 other hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorPeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
- Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07000617, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Pathologically confirmed diagnosis of extranodal NK/T-cell lymphoma
Inclusion criterion 1
Patients who received supportive care for anemia, neutropenia or thrombocytopenia within 7 days prior to start of study treatment.
Exclusion criterion 5
ECOG-PS 0\~2
Inclusion criterion 5
Peripheral blood absolute neutrophil count ≥1.5×10E9/L, platelet count ≥75×10E9/L and hemoglobin ≥90g/L
Inclusion criterion 6
Presence of at least 1 measurable lesion according to the 2014 Lugano revised criteria for response assessment
Inclusion criterion 4
Pregnant or lactating women, or patients of childbearing age unwilling to take contraceptive measures during the study period.
Exclusion criterion 2
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07000617, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Pathologically confirmed diagnosis of extranodal NK/T-cell lymphoma
- Age ≥18 years
- Ann Arbor stage I or II
- Presence of at least 1 measurable lesion according to the 2014 Lugano revised criteria for response assessment
- ECOG-PS 0\~2
- Peripheral blood absolute neutrophil count ≥1.5×10E9/L, platelet count ≥75×10E9/L and hemoglobin ≥90g/L
- Expected survival of at least 3 months
- Capable of understanding the content of this study, agreeing to participate in this study and signing the informed consent.
Exclusion Criteria:
- Unconfirmed pathological diagnosis of NK/T-cell lymphoma
- Pregnant or lactating women, or patients of childbearing age unwilling to take contraceptive measures during the study period.
- Patients with clinically significant prolonged QTc interval (>470ms in males, >480ms in females), ventricular tachycardia, atrial fibrillation, second or third degree atrioventricular block, acute myocardial infarction, congestive heart failure, severe or symptomatic coronary artery disease requiring medical treatment.
- Patients with large amount of pericardial effusions shown by echocardiogram.
- Patients who received supportive care for anemia, neutropenia or thrombocytopenia within 7 days prior to start of study treatment.
- Patients with severe active bleeding.
- Patients with pulmonary embolism, intracranial hemorrhage or acute cerebral infarction.
- Patients with active infectious disease.
- Patients who are mentally disabled or unable to understand or sign the informed consent form.
- Patients with other conditions judged as ineligible for this study by the investigators.
Quoted from ClinicalTrials.gov, NCT07000617, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07000617, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.